**Psychological morbidities and fatigue in patients with confirmed COVID-19 during disease outbreak: prevalence and associated biopsychosocial risk factors**

**Supplementary Material**

1. **Supplementary Tables**

**Table S1 Comparisons of patients with and without PTSD symptoms.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Protocols** | **PTSD symptoms present** (n=5) | **PTSD symptoms absent** (n=36) | ***P* value** |
| **Age**, Mean (±SD), y | 44.00 (±13.06)  | 38.60 (±9.01)  | 0.62a |
| **Sex** (F/M)  | 3/2  | 21/15  | 1c |
| **Education**, Median (range), y  | 9 (9-13)  | 12 (9.75-14)  | 0.27b |
| **Marital status**, n/N (%) |  |  | 1c |
| Married | 5/5 (100) | 31/36 (86.11) |  |
| Single/divorced/widowed  | 0/5 (0) | 5/36 (13.89) |  |
| **Clinical symptoms** |  |  |  |
| Fever, n/N (%) | 5/5 (100) | 29/36 (80.65) | 0.57c |
| Cough, n/N (%) | 4/5 (80) | 20/36 (55.56) | 0.58c |
| Muscle soreness, n/N (%) | 1/5 (20) | 4/36 (11.11) | 0.50c |
| Fatigue, n/N (%) | 2/5 (40) | 10/36 (27.78) | 0.97c |
| Headache, n/N (%) | 0/5 (0) | 2/36 (5.56) | 1c |
| Nausea, n/N (%) | 1/5 (20) | 4/36 (11.11) | 0.50c |
| Diarrhea, n/N (%) | 1/5 (20) | 5/36 (13.89) | 0.57c |
| Stomach ache, n/N (%) | 0/5 (0) | 2/36 (5.56) | 1c |
| Dyspnea, n/N (%) | 0/5 (0) | 2/36 (5.56) | 1c |
| **Physical comorbidity**  |  |  |  |
| Cardiovascular disease | 0/5 (0) | 0/36 (0) | - |
| Diabetes, n/N (%) | 1/5 (20) | 1/36 (2.78) | 0.23c |
| Hypertension, n/N (%) | 1/5 (20) | 5/36 (13.89) | 0.57c |
| Chronic obstructive pulmonary disease, n/N (%) | 0/5 (0) | 0/36 (0) | - |
| Chronic liver diseases, n/N (%) | 0/5 (0) | 2/36 (5.56) | 1c |
| Chronic kidney diseases, n/N (%) | 0/5 (0) | 0/36 (0) | - |
| Malignancy, n/N (%)  | 0/5 (0) | 0/36 (0) | - |
| **CT severity score**, Median (range), % | 75 (47.5-90) | 45 (15-80) | 0.15b |
| **Received steroid therapy**, n/N (%) | 0/5 (0) | 1/36 (2.78) | 1c |
| **SSRS** |  |  |  |
| Objective support | 6 (6-6.5) | 10 (8-13.75) | 0.005b |
| Subjective support | 26 (24-28) | 29 (25-31) | 0.23b |
| Utility of support | 5 (4.5-8) | 7 (6-9) | 0.13b |
| **SCSQ** |  |  |  |
| Active | 18 (10.5-27) | 23 (15.5-27.75) | 0.43b |
| Negative | 12.6 (±3.58) | 7.78 (±3.79) | 0.01a |
| **Perceived stigmatization** | 3 (2.5-3.5) | 2 (1-2) | 0.01b |
| **Intervals,** Median (range), d |  |  |  |
| Interval from initial symptom onset to psychometric assessment | 26 (21-30.5) | 27 (23.25-28.75) | 0.95b |
| Interval from hospitalization to psychometric assessment | 26 (21-28.5) | 27 (22.25-28) | 0.95b |
| Interval from most recent CT scan to psychometric assessment | 21 (16-23.5) | 21.5 (10.25-24.75) | 0.92b |

Values are expressed as mean ± SD, medians (interquartile ranges, IQR), and n/N (%). CT = computed tomography; PTSD = posttraumatic stress disorder; SSRS = social support rating scale; SCSQ = simple coping style questionnaire.

a The *P* value for the difference between the two groups was obtained by two sample *t*-test.

b The *P* value for the difference between the two groups was obtained by Mann–Whitney U test

c The *P* value for distribution difference between the two groups was obtained by the χ2 test or Fisher’s exact test.

**Table S2 Comparisons of patients with and without anxiety and/or depression symptoms.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Protocols** | **SAS/SDS symptoms Present** (n=11) | **SAS/SDS symptoms Absent** (n=30) | ***P* value** |
| **Age**, Mean (±SD), y | 38.09 (±10.18)  | 39.67 (±9.46)  | 0.62a |
| **Sex** (F/M)  | 8/3  | 16/14  | 0.45c |
| **Education**, Median (range), y  | 12 (12-14)  | 12 (9-14)  | 0.57b |
| **Marital status**, n/N (%) |  |  | 1c |
| Married | 10/11 (90.9) | 26/30 (86.67) |  |
| Single/divorced/widowed  | 1/11 (9.09) | 4/30 (13.33) |  |
| **Clinical symptoms** |  |  |  |
| Fever, n/N (%) | 9/11 (81.82) | 25/30 (83.33) | 1c |
| Cough, n/N (%) | 6/11 (54.55) | 18/30 (60) | 1c |
| Muscle soreness, n/N (%) | 2/11 (18.18) | 3/30 (10) | 0.86c |
| Fatigue, n/N (%) | 2/11 (18.18) | 10/30 (33.33) | 0.58c |
| Headache, n/N (%) | 1/11 (9.09) | 1/30 (3.33) | 0.47c |
| Nausea, n/N (%) | 0/11 (0) | 5/30 (16.67) | 0.37c |
| Diarrhea, n/N (%) | 1/11 (9.09) | 5/30 (16.67) | 0.91c |
| Stomach ache, n/N (%) | 0/11 (0) | 2/30 (6.67) | 1c |
| Dyspnea, n/N (%) | 0/11 (0) | 2/30 (6.67) | 1c |
| **Physical comorbidity**  |  |  |  |
| Cardiovascular disease | 0/11 (0) | 0/30 (0) | - |
| Diabetes, n/N (%) | 1/11 (9.09) | 1/30 (3.33) | 0.47c |
| Hypertension, n/N (%) | 1/11 (9.09) | 5/30 (16.67) | 1c |
| Chronic obstructive pulmonary disease, n/N (%) | 0/11 (0) | 0/30 (0) | - |
| Chronic liver diseases, n/N (%) | 0/11 (0) | 2/30 (6.67) | 1c |
| Chronic kidney diseases, n/N (%) | 0/11 (0) | 0/30 (0) | - |
| Malignancy, n (%) | 0/11 (0) | 0/30 (0) | - |
| **CT severity score**, Median (range), % | 35 (25-75) | 55 (15-80) | 0.72b |
| **Received steroid therapy**, n/N (%) | 0/11 (0) | 1/30 (3.33) | 1c |
| **SSRS** |  |  |  |
| Objective support | 6 (6-10) | 10.5 (8-14) | 0.01b |
| Subjective support | 24 (21-27) | 29 (26-31) | 0.01b |
| Utility of support | 7 (5-8) | 7.5 (6-10) | 0.09b |
| **SCSQ** |  |  |  |
| Active | 22 (11-27) | 24 (16-27) | 0.34b |
| Negative | 8.72 (±5.64) | 8.23 (±3.40) | 0.73a |
| **Perceived stigmatization**  | 2 (1-3) | 2 (1-3) | 0.90b |
| **Intervals,** Median (range), d |  |  |  |
| Interval from initial symptom onset to psychometric assessment | 28 (22-30) | 26.5 (23.75-28.25) | 0.61b |
| Interval from hospitalization to psychometric assessment | 28 (22-28) | 26.5 (22.75-28.25) | 0.70b |
| Interval from most recent CT scan to psychometric assessment | 23 (12-24) | 21 (10.5-23.5) | 0.50b |

Values are expressed as mean ± SD, medians (interquartile ranges, IQR), and n/N (%). SAS/SDS = self-rating anxiety/depression scale; CT = computed tomography; SSRS = social support rating scale; SCSQ = simple coping style questionnaire.

a The *P* value for the difference between the two groups was obtained by two sample *t*-test.

b The *P* value for the difference between the two groups was obtained by Mann–Whitney U test

c The *P* value for distribution difference between the two groups was obtained by the χ2 test or Fisher’s exact test.

**Table S3 Comparisons of patients with and without chronic fatigue problems.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Protocols** | **Fatigue problems Present** (n=22) | **Fatigue problems Absent** (n=19**)** | ***P* value** |
| **Age**, Mean (±SD), y | 37.27 (±10.51)  | 41.53 (±8.00)  | 0.62a |
| **Sex** (F/M)  | 15/7  | 9/10  | 0.29c |
| **Education**, Median (range), y  | 12 (9-14)  | 12 (9-14)  | 0.81b |
| **Marital status**, n/N (%) |  |  | 1c |
| Married | 19/22 (86.36) | 17/19 (89.47) |  |
| Single/divorced/widowed  | 3/22 (13.64) | 2/19 (10.53) |  |
| **Clinical symptoms** |  |  |  |
| Fever, n/N (%) | 19/22 (86.36) | 15/19 (78.95) | 0.83c |
| Cough, n/N (%) | 13/22 (59.09) | 11/19 (57.89) | 0.94c |
| Muscle soreness, n/N (%) | 5/22 (22.73) | 0/19 (0) | 0.08c |
| Fatigue, n/N (%) | 8/22 (36.36) | 4/19 (21.05) | 0.28c |
| Headache, n/N (%) | 1/22 (4.55) | 1/19 (5.26) | 1c |
| Nausea, n/N (%) | 2/22 (9.09) | 3/19 (15.79) | 0.86c |
| Diarrhea, n/N (%) | 4/22 (18.18) | 2/19 (10.53) | 0.80c |
| Stomach ache, n/N (%) | 0/22 (0) | 2/19 (10.53) | 0.21c |
| Dyspnea, n/N (%) | 1/22 (4.55) | 1/19 (5.26) | 0.90c |
| **Physical comorbidity**  |  |  |  |
| Cardiovascular disease | 0/22 (0) | 0/19 (0) | - |
| Diabetes, n/N (%) | 1/22 (4.55) | 1/19 (5.26) | 1c |
| Hypertension, n/N (%) | 2/22 (9.09) | 4/19 (21.05) | 0.52c |
| Chronic obstructive pulmonary disease, n/N (%) | 0/22 (0) | 0/19 (0) | - |
| Chronic liver diseases, n/N (%) | 0/22 (0) | 2/19 (6.90) | 0.21c |
| Chronic kidney diseases, n/N (%) | 0/22 (0) | 0/19 (0) | - |
| Malignancy, n/N (%)  | 0/22 (0) | 0/19 (0) | - |
| **CT severity score**, Median (range), % | 32.5 (15-80) | 65 (35-90) | 0.14b |
| **Received steroid therapy**, n/N (%) | 0/22 (0) | 1/19 (5.26) | 0.46c |
| **SSRS** |  |  |  |
| Objective support | 9 (6-13.25) | 10 (6-13) | 0.68b |
| Subjective support | 26.5 (24-29.25) | 29 (26-31) | 0.02b |
| Utility of support | 7 (5.75-8) | 7 (6-10) | 0.17b |
| **SCSQ** |  |  |  |
| Active | 23 (15-27) | 23 (15-29) | 0.79b |
| Negative | 9.01 (±3.77) | 7.53 (±4.30) | 0.22a |
| **Perceived stigmatization** | 2 (1.75-3) | 2 (1-2) | 0.48b |
| **Intervals,** Median (range), days |  |  |  |
| Interval from initial symptom onset to psychometric assessment | 27.5 (24.75-30) | 25 (22-28) | 0.18b |
| Interval from hospitalization to psychometric assessment | 27.5 (23.75-29.25) | 25 (22-28) | 0.17b |
| Interval from most recent CT scan to psychometric assessment | 22 (12.75-24.25) | 21 (9-23) | 0.32b |

Values are expressed as mean ± SD, medians (interquartile ranges, IQR), and n/N (%). CT = Computed Tomography; SSRS = social support rating scale; SCSQ = simple coping style questionnaire.

a The *P* value for the difference between the two groups was obtained by two sample *t*-test.

b The *P* value for the difference between the two groups was obtained by Mann–Whitney U test

c The *P* value for distribution difference between the two groups was obtained by the χ2 test or Fisher’s exact test.